Tag: Alzheimer s treatment

In January 2023, the U.S. Food and Drug Administration (FDA) initially rejected Eli Lilly's application for accelerated approval of its Alzheimer's drug, donanemab, citing a limited number of patients with adequate long-term data. This was not the only regulatory hurdle the treatment would face, as the European Medicines Agency (EMA) also refused authorization later due to an unfavorable risk-benefit assessment.

The global AI in drug discovery market was valued at $1.5 billion in 2023 and is projected to soar to $20.30 billion by 2030 [1.9.5]. This explosion in technology is accelerating the hunt for the answer to the question: **what is the next big drug?**

Approved by the FDA in 1993, tacrine was the first cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease [1.2.3, 1.4.4]. This article explores the question, 'What is tacrine used for?', its mechanism, and its place in medical history.

Did you know that the spider lily, a beautiful but toxic plant in the *Amaryllidaceae* family, is a source of several potent alkaloids with significant pharmacological interest? Researchers are actively investigating what drug is in the spider lily, with compounds showing promise in treating conditions like cancer and Alzheimer's disease.

The 2021 FDA decision to grant accelerated approval to the Alzheimer's drug Aduhelm sparked a major controversy, serving as a prominent example of a potential meaning for 'Adu pharmacy'. To correctly understand the phrase, one must explore several distinct definitions, including Aduhelm, hospital pharmacy automation systems, and an academic institution.

The U.S. Food and Drug Administration (FDA) approved donanemab (brand name Kisunla) in July 2024 for treating early symptomatic Alzheimer's disease. This monoclonal antibody, developed by Eli Lilly, is specifically designed to target and help clear beta-amyloid plaques from the brain. Understanding the meaning of Donanemab involves grasping its innovative mechanism and potential to slow the disease's progression.